 SOUTH SAN FRANCISCO, Calif., July 14, 2021 GLOBE NEWSWIRE -- Nkarta, Inc. Nasdaq: NKTX, a biopharmaceutical company developing engineered natural killer NK cell therapies to treat cancer, today announced that it has signed a lease agreement for a facility to support research and development and future commercial manufacturing of Nkartas cell therapy pipeline. The new facility will also serve as the companys headquarters with office space and research facilities. The manufacturing center will be custom designed to complement Nkartas state-of-the-art technology platform and optimize the production of its multiple off-the-shelf NK cell therapy investigational products. Nkarta plans to produce materials for potential pivotal clinical trials and commercial launch at the new center. 